ID   rCalu-6
AC   CVCL_F0Q6
RX   PubMed=28273808;
CC   Population: Caucasian.
CC   Characteristics: Can be maintained in the presence of 20 muM of 5-fluorouracil. Shows cross-resistance to 5'-deoxy-5-fluorouridine (5'-DFUR), oxaliplatin (L-OHP) and cisplatin (PubMed=28273808).
CC   Selected for resistance to: ChEBI; CHEBI_46345; 5-fluorouracil (5-FU).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gln61Lys (c.180_181TC>CA) (c.180_181delinsCA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
CC   Cell type: Epithelial cell; CL=CL_0000066.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0236 ! Calu-6
SX   Female
AG   61Y
CA   Cancer cell line
DT   Created: 14-08-25; Last updated: 14-08-25; Version: 1
//
RX   PubMed=28273808; DOI=10.3390/ijms18030547; PMCID=PMC5372563;
RA   Russo, Annapina
RA   Saide, Assunta
RA   Smaldone, Silvia
RA   Faraonio, Raffaella
RA   Russo, Giulia
RT   "Role of uL3 in multidrug resistance in p53-mutated lung cancer cells.";
RL   Int. J. Mol. Sci. 18:547.1-547.16(2017).
//